Opsumit (macitentan)

17:16 EST 22nd November 2017 | BioPortfolio

OPSUMIT is an endothelin receptor antagonist (ERA) indicated for the treatment of pulmonary arterial hypertension (PAH, WHO Group
I) to delay disease progression. Disease progression included: death, initiation of intravenous (IV) or subcutaneous prostanoids, or clinical
worsening of PAH (decreased 6-minute walk distance, worsened PAH symptoms and need for additional PAH treatment). OPSUMIT also reduced hospitalization for PAH.

For full details open -

Quick Search

review and buy Opsumit (macitentan) market research data and corporate reports here